Lemborexant 5 mg + Control (placebo) group

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Delirium - Postoperative

Conditions

Delirium - Postoperative, Cardiac Surgery, Cardiac Surgery Subjects, Orexin Antagonist, Feasibility Studies, Sleep, In-hospital Mortality

Trial Timeline

May 1, 2025 → Apr 30, 2027

NCT ID

NCT06648681

About Lemborexant 5 mg + Control (placebo) group

Lemborexant 5 mg + Control (placebo) group is a phase 2 stage product being developed by Eisai for Delirium - Postoperative. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06648681. Target conditions include Delirium - Postoperative, Cardiac Surgery, Cardiac Surgery Subjects.

What happened to similar drugs?

5 of 13 similar drugs in Delirium - Postoperative were approved

Approved (5) Terminated (3) Active (6)

✅Rivastigmine + PlaceboNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ParecoxibPfizerApproved

✅Cyclopofol + PropofolHaisco Pharmaceutical GroupApproved

✅Dexmedetomidine Hydrochloride GroupBrain BiotechApproved

🔄Suvorexant + PlaceboMerckPhase 3

🔄Rivastigmine prevention of deliriumNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06648681	Phase 2	Recruiting	May 1, 2025	Apr 30, 2027	Delirium - Postoperative

Competing Products

17 competing products in Delirium - Postoperative

See all competitors

Product	Company	Stage	Hype Score
Suvorexant + Placebo	Merck	Phase 3	40
Suvorexant 20 mg + Placebo	Merck	Phase 2	35
Rivastigmine + Placebo	Novartis	Approved	35
Rivastigmine prevention of delirium	Novartis	Phase 3	40
Rivastigmine transdermal patch + placebo patch	Novartis	Phase 3	40
Rivastigmine Patch	Novartis	Approved	43
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Parecoxib	Pfizer	Approved	39
Dexmedetomidine + Placebo	Pfizer	Phase 3	32
Pregabalin	Pfizer	Phase 3	40
Dexmedetomidine + Midazolam	Pfizer	Phase 3	47
Propofol + Dexmedetomidine	Pfizer	Pre-clinical	26
Dexmedetomidine + Saline placebo	Pfizer	Phase 2/3	38
Cyclopofol + Propofol	Haisco Pharmaceutical Group	Approved	39
Dexmedetomidine + Sodium chloride 0.9%	Baxter	Phase 3	37
Dexmedetomidine Hydrochloride Group	Brain Biotech	Approved	40
Dexmedetomidine sublingual film	BioXcel Therapeutics	Phase 2	17